Sigyn Therapeutics, Inc. (OTCQB: SIGY) released a shareholder update on March 13, 2026, authored by CEO Jim Joyce, detailing the company's strategic initiatives including a potential merger with a Nasdaq-listed company and the sale of certain assets. The update comes as the company faces financial challenges that have hindered its ability to uplist to a major exchange.
Joyce, who previously founded Aethlon Medical and led the development of the Hemopurifier—a TIME magazine 'Top 25 Invention'—outlined Sigyn's progress with CardioDialysis, a device designed to treat cardiovascular disease, sepsis, and traumatic brain injury. CardioDialysis targets cholesterol-transporting lipoproteins and inflammatory molecules, and is intended for use on dialysis machines already present in over 7,500 U.S. clinics, potentially expanding access beyond the 60 specialized apheresis centers currently available for lipoprotein apheresis.
The company's efforts to uplist to Nasdaq were thwarted by a regulatory catch-22: Nasdaq required SEC-approved investors before listing approval, while the SEC needed Nasdaq's contingent approval before deeming the registration statement effective. This led to the withdrawal of the registration statement underlying the financing. As a result, Sigyn is now exploring a merger with a Nasdaq-listed company at risk of not meeting the $5 million minimum market value of listed securities requirement. Joyce also mentioned the potential sale of assets, including the traumatic brain injury indication, which has emerged as a valuable asset.
Sigyn's pipeline includes ImmunePrep, ChemoPrep, and ChemoPure for cancer therapy, but the company's immediate focus is on strategic transactions to secure capital without further diluting shareholder value. Joyce encouraged shareholders to review his January 15th update for more details on these strategies.
With 2,330,042 shares outstanding as of March 11, 2026, Sigyn Therapeutics continues to advance its dialysis-like therapies despite the financial hurdles. The outcome of the merger and asset sale discussions will be critical for the company's future direction and its ability to bring CardioDialysis to market.
